First trimester treatment for malaria could change with the results of 1 of the most robust meta-analyses to date that compared artemisinin-based therapy vs quinine.
A 15-year-old African American girl is admitted to the emergency department complaining of fever, vomiting, headache, back pain, and chills.
Accurate and rapid diagnostics methods are needed to inform initial clinical decision making for patients with hip monoarthritis.
The Phase 2b study is in the process of enrolling 400 people to evaluate multiple dosing regimens. PaxVax expects the results in early 2019.
Vector-borne diseases represent an increasing problem in the United States, with a more than 2-fold increase in the number of annual reports from 2004 to 2016.
Women in the United States with uncomplicated malaria during the first trimester of pregnancy should be treated with the currently recommended options of either mefloquine or quinine plus clindamycin. However, when neither of these options is available, artemether-lumefantrine should be considered for treatment.
As long-term neurocognitive deficits can occur as a result of severe malaria, researchers assessed the potential neuroprotective effect of inhaled nitric oxide on children with the infection.
Many patients with a previous West Nile virus infection have abnormalities on neurologic examination several years after they were infected.
The FDA has granted accelerated approval for benznidazole as the first US treatment of Chagas disease in children ages 2 to 12 years.
Placental malaria during pregnancy may raise the risk of malaria infection in childhood by promoting maternal microchimerism, in which the fetus acquires noninherited maternal cells during pregnancy. Maternal microchimerism may be the mechanism by which the fetus develops tolerance to malaria antigens, leading to an impaired malaria-specific immune response.
3 IV doses of PfSPZ vaccine conferred protection after immunization against different Pf strains of malaria than the one the vaccine came from.
Investigational vaccine is designed to trigger an immune response to mosquito saliva rather than to a specific virus or parasite carried by mosquitoes.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Importance of PrEP for People Involved in Criminal Justice Systems
- Increasing Incidence of Syphilis in People With HIV
- FDA: Possible Risk of Neural Tube Birth Defects With Certain Antiretroviral Agents
- Fungal Infections of the CNS: Diagnostic and Treatment Approaches
- Study Supports Development of a Vaccine for Recurrent Vulvovaginal Candidiasis
- Early Flow Cytometry Predictive of Clinical Deterioration in Sepsis
- Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?
- Hepatitis C Virus Infection Linked to Gut Dysbiosis
- Two Hepatitis C Virus Infection Treatments to Be Discontinued
- Antibiotic Use During Pregnancy May Increase Risk for Childhood Asthma